Related Experiment Video
Updated: Jan 6, 2026
Examining Monosynaptic Connections in Drosophila Using Tetrodotoxin Resistant Sodium Channels
Published on: February 14, 2018
Akt Pathway Inhibition of the Solenopsin Analog, 2-Dodecylsulfanyl-1,-4,-5,-6-tetrahydropyrimidine
Nne E Uko1, Osman F Güner2, J Phillip Bowen1
1Department of Pharmaceutical Sciences, College of Pharmacy, Mercer University, Atlanta, GA, U.S.A.
Background/Aim:
The P13K/Akt signaling pathway is a growth-regulating cellular pathway that is constitutively activated in a variety of human cancers. In previous studies, we reported that a solenopsin analog, compound B (MU-06-SC-608-7), shows inhibitory effects on Akt phosphorylation at a key activation site, as well as on proliferation of tumorigenic cells at sub-micromolar concentrations. The purpose of this study was to evaluate the effect of compound B on downstream effectors of Akt kinase, phosphorylation of Akt at a second activation site, Akt kinase activity in vitro, tumorigenic cell viability and other signaling pathways.
Materials And Methods:
Western blot analyses were performed using WBras1 epithelial and H2009 human carcinoma cells and cell viability assays were performed on H2009 cells. In vitro Akt kinase assays were performed using a commercially available kit.
Results:
Compound B decreased the phosphorylation of Akt at the Thr308 activation site and key downstream effectors of Akt kinase, but did not directly inhibit Akt kinase. Substantial decreases in cell viability were observed at concentrations above 5 μM. No effect was seen on ERK or JNK pathways.
Conclusion:
The results earmark this compound for further studies as a potential targeted cancer therapy.
Insights
Compound B, a solenopsin analog, inhibits Akt phosphorylation and reduces cancer cell viability. Further research is warranted for its potential as a targeted cancer therapy.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- The PI3K/Akt pathway regulates cell growth and is often activated in human cancers.
- Compound B (a solenopsin analog) previously showed inhibition of Akt phosphorylation and tumor cell proliferation.
Purpose of the Study:
- To evaluate Compound B's effects on Akt kinase downstream effectors.
- To assess Compound B's impact on Akt phosphorylation at a second site, Akt kinase activity, and cancer cell viability.
- To investigate Compound B's influence on other signaling pathways.
Main Methods:
- Western blot analysis in epithelial and carcinoma cell lines.
- Cell viability assays.
- In vitro Akt kinase assays.
Main Results:
- Compound B reduced Akt phosphorylation at Thr308 and downstream effectors.
- Significant decreases in cancer cell viability were observed at concentrations >5 μM.
- Compound B did not directly inhibit Akt kinase activity and had no effect on ERK or JNK pathways.
Conclusions:
- Compound B demonstrates potential as a targeted cancer therapeutic.
- Further studies are recommended to explore Compound B's therapeutic applications.
Related Concept Videos
01:19Allosteric Proteins-ATCase
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis...
01:11Channel Rhodopsins
Rhodopsins belong to the family of cell surface proteins called G-protein coupled receptors,...
01:30Ligand-Gated Ion Channel Receptor: Gating Mechanism
01:31The Intrinsic Apoptotic Pathway
01:25cAMP-dependent Protein Kinase Pathways